Table C.1.
Country | N | GEN | CHL | AMP | CTX | CAZ | MEM | TGC | NAL | CIP | AZM | COL | SMX | TMP | TET |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Belgiuma | 2 | 0 | 0 | 100 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 100 | 0 | 100 |
Croatiaa | 5 | 0 | 20 | 100 | 0 | 0 | 0 | 0 | 20 | 20 | 0 | 0 | 100 | 20 | 80 |
Francea | 3 | 0 | 0 | 66.7 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 66.7 | 33.3 | 100 |
Spaina | 2 | 50 | 0 | 100 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 100 | 50 | 100 |
Total (4 MSs) | 12 | 8.3 | 8.3 | 91.7 | 0 | 0 | 0 | 0 | 8.3 | 8.3 | 0 | 0 | 91.7 | 25 | 91.7 |
ECOFFs: epidemiological cut‐off values; N: number of isolates tested; MSs: Member States; GEN: gentamicin; CHL: chloramphenicol; AMP: ampicillin; CTX: cefotaxime; CAZ: ceftazidime; MEM: meropenem; TGC: tigecycline; NAL: nalidixic acid; CIP: ciprofloxacin; AZM: azithromycin; COL: colistin; SMX: sulfamethoxazole; TMP: trimethoprim; TET: tetracycline.
The occurrence of resistance is assessed on less than 10 isolates and should only be considered as part of the total of MSs data.